anavar cycle for women

Anavar cycle for women (vinca alkaloid produced by semi-synthetic) -. Vinca alkaloids antitumor agent of the group
violate tubulin polymerization during cell mitosis. Blocks mitosis in phase G2 + M and causes destruction of cells in interphase or at the following mitosis. It acts primarily on mitotic microtubules; with high doses may affect the axonal microtubules. The effect of helix tubulin caused by anavar cycle for women, is less pronounced than that of vincristine.

Pharmacokinetics
Following intravenous administration of the drug can be traced three-phase kinetics. The average half-life in the terminal phase is 40 (27,7-43,6) hours.Relationship to plasma proteins is 79,6-91,2%. Intensively binds to platelets, lymphocytes, alpha1-acid glycoprotein, lipoproteins and albumin. It penetrates into the fabric and retained therein for a long time. Large amounts determined in spleen, liver, kidney, lung, and thymus, moderate – and heart muscles, the minimum – in adipose tissue, brain and bone marrow. The concentration in the lungs of 300 times the concentration in plasma. It forms a number of metabolites; One of the metabolites – diatsetilvinorelbin retains antitumor activity. It is metabolized in the liver. Write mainly in the bile.

Indications

 

  • non-small cell lung cancer;
  • mammary cancer.

Contraindications

 

  • hypersensitivity to vinca alkaloids;
  • expressed human liver;
  • initial neutrophil count <1000 cells / microliter of blood
  • Radiotherapy hepatobiliary area
  • pregnancy and lactation;

With care – respiratory failure, inhibition of bone marrow hematopoiesis (including after previous chemotherapy or radiation therapy), constipation or intestinal obstruction phenomena in history, a history of neuropathy.

Dosing and Administration

Vinkarelbin applied as a monotherapy, or in combination with other anticancer agents. When choosing the dose and mode of administration in each individual case should be referred to the specialized literature.
We introduce a strictly intravenously in a 15-20 minute infusion.
In monotherapy the usual dose is 25-30 mg / m 2 body surface area once a week. The drug was diluted in 0.9% sodium chloride or 5% dextrose solution to a concentration of 1.5-3.0 mg / ml. After administration the vein should be flushed by introducing an additional 50-100 mL of 0.9% sodium chloride solution.

Correction of dosage regimen Vinkarelbina in zavismosti of hematological parameters:

 

Number of granulocytes in the daily administration (cells / mm) The percentage of the starting dose Vinkarelbina
> / = 1500 100 %
1499-1000 50 %
<1000 The drug is not administered. Is repeated to determine the number of granulocytes after 1 week. If, due to granulocytopenia had to refrain from 3 weekly injections of the drug, the use of anavar cycle for women are advised to stop
In patients with hyperthermia and / or sepsis, granulocytopenia on the background during the treatment period or skip 2 consecutive weekly injections of the drug due to the low numbers of granulocytes in subsequent dose administrations should constitute a percentage of the previous dose:
> / = 1500 75%
1499-1000 37.5%
<1000 the drug is not administered.

Correction of dosage regimen Vinkarelbina in hepatic impairment: in patients with hepatic insufficiency Vinkarelbin should be administered with caution, with the appearance of hyperbilirubinemia during treatment Vinkarelbinom subsequent doses should be reduced according to the following guidelines:

 

The concentration of total bilirubin (mmol / l) The percentage of the starting dose Vinkarelbina
</ = 34.2 100 %
35.9 – 51.3 50 %
> 51.3 25%

For patients with a body surface area of ≥ 2 m 2 the single dose Vinkarelbina should not exceed 60 mg.
Children: Safety and efficacy in children Vinkarelbina not been studied.
Elderly: any special instructions for use Vinkarelbina absent in the elderly.

Side effect

From the side of hematopoiesis: granulocytopenia, anemia, and rarely – thrombocytopenia. The smallest number of granulocytes occurs 7-10 days after initiation of therapy, recovery occurs in the next 7-14 days. From the nervous system: the reduction or loss of deep tendon reflexes, paresthesia, hypersthesia, weakness in the legs, pain in the jaw, headache, paresis bowel, rarely paralytic ileus. On the part of the digestive system: nausea, vomiting, anorexia, constipation, diarrhea, dysphagia, mucositis, pancreatitis, increased bilirubin, and increased activity of “liver” transaminases. On the part of the respiratory system: difficulty breathing, shortness of breath, bronchospasm, interstitial pneumonia, acute respiratory distress syndrome. Since the cardiovascular system: chest pain, increased or decreased blood pressure, tachycardia, rarely – myocardial infarction, pulmonary edema Local reactions: pain or redness at the injection site; when extravasation – cellulitis, phlebitis, and possibly necrosis of surrounding tissues. Other: fatigue, alopecia, myalgia, arthralgia, skin rashes, allergic reactions, hot flashes to the face, increased creatinine, hyponatraemia, hemorrhagic cystitis and the syndrome of inappropriate secretion of antidiuretic hormone.

Overdose

A specific antidote is not known. In the case of an overdose the patient should be hospitalized and carefully monitor the function of vital organs. The main expected manifestations of overdose include bone marrow suppression and peripheral neuropathy. Treatment is symptomatic.

The interaction with other drugs and other interactions

When combined with mitomycin C may develop acute respiratory failure.
When used in conjunction with paclitaxel increases the risk of neurotoxicity.
When used in conjunction with cisplatin is enhanced granulocytopenia.
Application to the background radiation therapy leads to radiosensitization.
The drug should be used with caution with inhibitors of cytochrome R450-3A.

special instructions

Vinkarelbinom Treatment should be under the supervision of a physician who has experience with anticancer drugs.
Treatment Vinkarelbinom carried out under strict hematological control, determining the number of white blood cells, granulocytes, and hemoglobin level prior to each regular injection.
If abnormal liver dose Vinkarelbina function should be reduced.
If the kidney function must be enhanced monitoring of the patient.
If signs of neurotoxicity of drug treatment should be discontinued.
in case of shortness of breath, cough, or hypoxia of unknown etiology should examine the patient to rule out pulmonary toxicity.
If extravasation of drug infusion should be discontinued immediately, the remaining dose administered in another vein.
while in for at least three months after cessation of therapy is necessary to use reliable methods of contraception.
in case of contact with eyes Vinkarelbina should be abundantly and thoroughly with water.